Genetics/biotech expert offers comments & availability on IVG (in vitro gametogenesis) major breakthrough

A groundbreaking study demonstrating the most advanced form of in vitro gametogenesis (making eggs from stem cells, IVG) was published Thursday in Science. See STAT’s coverage of the study.  Regarding the study and breakthrough, Dr. Kevin Doxzen offers the below comments…

UM School Of Medicine Researchers Receive NIH Avant Garde Award For Out-Of-Box, Innovative Concept To Cure HIV And Treat Co-Existing Addiction

University of Maryland School of Medicine (UMSOM) Professor of Diagnostic Radiology & Nuclear Medicine, Linda Chang, MD, MS, received the National Institute on Drug Abuse (NIDA) 2021 Avant Garde Award (DP1) for HIV/AIDS and Substance Use Disorder Research — a National Institutes of Health (NIH) Director’s Pioneer Award.

With gene therapy, scientists develop opioid-free solution for chronic pain

A gene therapy for chronic pain could offer a safer, non-addictive alternative to opioids. Researchers at the University of California San Diego developed the new therapy, which works by temporarily repressing a gene involved in sensing pain. It increased pain tolerance in mice, lowered their sensitivity to pain and provided months of pain relief without causing numbness.

Potential Target for Treating Many Cancers Found Within GLI1 Gene

Scientists from the Stanley Manne Children’s Research Institute at Ann & Robert H. Lurie Children’s Hospital of Chicago found that a region within the DNA of the cancer-promoting GLI1 gene is directly responsible for regulating this gene’s expression. These findings, published in the journal Stem Cells, imply that this region within GLI1 could potentially be targeted as cancer treatment, since turning off GLI1 would interrupt excessive cell division characteristic of cancer.

Mount Sinai-Led Team Builds First Model of the Progression of Acute Myeloid Leukemia using CRISPR

A research team led by the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) has built the first cellular model to depict the evolution of acute myeloid leukemia (AML), from its early to late stages. By using gene editing technologies to alter genes that make cells malignant, the team was able to identify potential therapeutic targets for early disease stages. The study was reported in the journal Cell Stem Cell in February.

Biotechnology research and policy expert joins Thunderbird School of Global Management and Sandra Day O’Connor College of Law at ASU through World Economic Forum fellowship

Thunderbird School of Global Management announces the first of two prestigious Hoffmann Fellowships appointed in collaboration with the World Economic Forum for post-doctoral research and policy innovation at the intersection of society, science and technology.

Gene-Editing ‘Scissor’ Tool May Also be a ‘Dimmer Switch’

In a series of experiments with laboratory-cultured bacteria, Johns Hopkins scientists have found evidence that there is a second role for the widely used gene-cutting system CRISPR-Cas9 — as a genetic dimmer switch for CRISPR-Cas9 genes. Its role of dialing down or dimming CRISPR-Cas9 activity may help scientists develop new ways to genetically engineer cells for research purposes.

Synthetic Biology and Machine Learning Speed the Creation of Lab-Grown Livers

Researchers at the University of Pittsburgh School of Medicine have combined synthetic biology with a machine learning algorithm to create human liver organoids with blood and bile handling systems. When implanted into mice with failing livers, the lab-grown replacement livers extended life.

Cancer-Fighting Gene Restrains ‘Jumping Genes’

DALLAS – Oct. 29, 2020 – About half of all tumors have mutations of the gene p53, normally responsible for warding off cancer. Now, UT Southwestern scientists have discovered a new role for p53 in its fight against tumors: preventing retrotransposons, or “jumping genes,” from hopping around the human genome. In cells with missing or mutated p53, the team found, retrotransposons move and multiply more than usual. The finding could lead to new ways of detecting or treating cancers with p53 mutations.

FSU CRISPR EXPERTS AVAILABLE TO COMMENT ON CHEMISTRY NOBEL PRIZE

FOR IMMEDIATE RELEASE    CONTACT: Kathleen Haughney, University Communications (850) 644-1489; [email protected]  @FSUResearch    Florida State University professors as well as scientists around the world have benefited from the advent of CRISPR, the sophisticated genome editing technology that has revolutionized genetic research.  The scientists Emmanuelle Charpentier and Jennifer A. Doudna received…

American Chemical Society’s president comments on award of 2020 Nobel Prize in Chemistry

On behalf of the American Chemical Society (ACS), President Luis Echegoyen, Ph.D., congratulates today’s winners of the Nobel Prize in Chemistry: Emmanuelle Charpentier, Ph.D., and Jennifer A. Doudna, Ph.D. The Royal Swedish Academy of Sciences awarded the prize “for the development of a method for genome editing.”

The Gut Microbiome, CRISPR/Cas-9, and More Featured in August 2020 Toxicological Sciences

The August 2020 issue of Toxicological Sciences includes exciting advances in toxicology research. The edition features pieces on biotransformation, toxicokinetics, and pharmacokinetics; developmental and reproductive toxicology; and more.

Scientists Aim Gene-Targeting Breakthrough Against COVID-19

Scientists at Berkeley Lab and Stanford have joined forces to aim a gene-targeting, antiviral agent called PAC-MAN against COVID-19.

Grant will help scientists break new ground in gene editing

A new grant from the National Institutes of Health will allow Iowa State University scientists to continue to develop gene editing technologies to model human disease in zebrafish. The research aims to build new tools to determine which genes have therapeutic potential to treat human genetic diseases that affect the cardiovascular, immune and nervous systems.

Xenobiotic Receptor Activation, CRISPR/Cas9, Magnetic Resonance-Guided Radiotherapy, and More Featured in May 2020 Toxicological Sciences

During these difficult times, the Society of Toxicology’s official journal, Toxicological Sciences, remains a source for leading research in toxicology, including in the areas of biomarkers, carcinogenesis, and organ-specific toxicology.

“CRISPR: A Screener’s Guide” Headlines the March Edition of SLAS Discovery

The March edition of SLAS Discovery features the cover article, “CRISPR: A Screener’s Guide,” by Carlos le Sage, Ph.D., Steffen Lawo, Ph.D., and Benedict C.S. Cross, Ph.D., (Horizon Discovery, United Kingdom). In their review, the authors discuss how CRISPR-Cas9 systems are being used widely throughout the drug discovery process and the development of new precision medicines.

Serum Biomarkers, Metabolite Indicators for Kidney Toxicity, Estrogenic Compound Screening, and More Featured in February 2020 Toxicological Sciences

The February 2020 issue of Toxicological Sciences includes cutting-edge research spanning the toxicological field, from molecular, biochemical, and systems toxicology and nanotoxicology to regulatory science, risk assessment, and decision-making.

Opening Up DNA to Delete Disease

Protein editorial assistants are clearing the way for cut-and-paste DNA editors, like CRISPR, to access previously inaccessible genes of interest. Opening up these areas of the genetic code is critical to improving CRISPR efficiency and moving toward futuristic, genetic-based assaults on disease. The DNA-binding editorial assistants were devised by a U.S.-based team of bioengineers, who describe their design in APL Bioengineering.

New CRISPR-based System Targets Amplified Antibiotic-resistant Genes

Researchers have developed a new CRISPR-based gene-drive system that more efficiently inactivates a gene rendering bacteria antibiotic-resistant. The new system leverages technology developed by UC San Diego biologists in insects and mammals that biases genetic inheritance of preferred traits called “active genetics.”

NEW TWIST ON CRISPR TECHNOLOGY

Researchers at the University of Delaware, using the revolutionary new genetic technology known as CRISPR/Cas9 have found a way to improve the efficiency and precision of the way enzymes work together to produce certain biochemical reactions in cells. Their new application essentially creates a dynamic assembly line that can lead to advances in pharmaceuticals, agriculture and biofuels.